Sylvain Chemtob
M.D., Ph.D., Professor
Dentistry
swedish dental AB
Sweden
Biography
Chemtob is a reputed neonatal pharmacologist and physiologist, with expertise on mechanisms implicated in ischemic retinopathies and other conditions involving inflammation including preterm labor. He has also initiated a new technology to develop peptidomimetic drugs that target membrane receptors; some compounds are licensed to industry, and one which successfully completed Phase Ib clinical trial is Phase II-ready (PDC Biotech). His seminal work also triggered the approval (EMEA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus, which is now standard of care. His work in pharmacology led to discovery of nuclear GPCRs. Sylvain Chemtob is author of over 260 articles reported in major journals, as well as inventor of 33 patents. He has trained so far 46 graduate students and 29 post-graduate fellows (MDs and PhDs)
Research Interest
Dentistry
